Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Bertagnolli Monica reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. director Monica Bertagnolli received an equity grant rather than cash fees for board service. She was issued 83 fully vested Restricted Stock Units (RSUs) on common stock in lieu of quarterly retainer fees of $16,875. Each RSU equals one share of common stock, bringing her direct holdings to 5,374 shares after this grant.
Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. director Roy D. Baynes received a grant of 83 shares of common stock in the form of Restricted Stock Units. These RSUs were issued in lieu of quarterly board retainer fees of $16,875 and were fully vested at issuance. Following this award, Baynes directly holds 18,512 shares of Natera common stock. Each RSU represents a right to receive one share of common stock, so the grant functions as non-cash, stock-based compensation for his board service.
Natera, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 11, 2026. Proposals include electing three Class II directors and one Class I director, ratifying Ernst & Young LLP as auditor, and holding advisory votes on executive pay and pay-vote frequency, with the board favoring annual votes.
Stockholders are also asked to approve an amendment to the Amended and Restated 2015 Equity Incentive Plan to add 3,200,000 shares, on top of 4,961,133 shares remaining available and 11,153,080 shares already subject to outstanding awards as of March 31, 2026. The company highlights 2025 performance of $2,306.1 million in total revenue, about 36% growth over 2024, roughly 3.5 million tests processed, and about 800,800 oncology tests, as well as the acquisition of Foresight Diagnostics and over 350 cumulative peer‑reviewed publications supporting its oncology, women’s health, and organ health tests.
Natera, Inc. director and co-founder Jonathan Sheena reported indirect open-market sales of common stock by family trusts associated with him. The trusts sold a total of 1,500 shares on April 17, 2026 in two transactions at weighted average prices of about $199.59 and $199.66 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 7, 2024. The sales were executed by the Caraluna 1 and Caraluna 2 Trusts, which hold the shares for trust beneficiaries, and Sheena disclaims beneficial ownership of those securities. Following these transactions, the filing shows 259,255 Natera shares held directly by Sheena and 20,282 shares reported as held indirectly through each trust.
Natera, Inc. filed an initial insider ownership statement for Eric H. Rubin
Natera, Inc. Executive Chairman Matthew Rabinowitz exercised stock options and used shares to cover taxes. He exercised options to acquire 58,292 shares of Common Stock at an exercise price of $9.59 per share. To satisfy tax obligations, 27,610 shares of Common Stock were withheld at $204.87 per share. Following these transactions, he held 2,383,162 shares of Common Stock directly, plus 5,000 shares held indirectly by his spouse.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, conducted open-market sales of company common stock. On April 1, 2026, he sold a total of 8,400 shares at weighted average prices within disclosed ranges between $200.47 and $205.50 per share under a pre-arranged Rule 10b5-1 trading plan. Following these sales, he continued to hold 224,885 shares of Natera common stock directly.
Natera, Inc. executive Solomon Moshkevich reported selling 3,000 shares of Common Stock in open-market transactions. On April 1, 2026, he executed three sales of 1,048, 1,000, and 952 shares at weighted average prices of $201.3206, $202.3638, and $203.3106 per share.
The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024, indicating they were scheduled in advance. After these transactions, Moshkevich directly owns 147,882 shares of Natera common stock.
Natera, Inc. Executive Chairman Matthew Rabinowitz exercised stock options to acquire 41,708 shares of Common Stock. He exercised a fully exercisable option with a strike price of $9.59 per share, converting it into 41,708 Common shares on a one-for-one basis.
Following the transaction, he directly holds 2,352,480 shares of Natera Common Stock and 58,292 stock options. In addition, 5,000 Common shares are reported as indirectly owned by his spouse.